Nj. Wandersee et al., Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells, BLOOD, 97(12), 2001, pp. 3972-3975
Thrombosis is a life-threatening complication of hemolytic anemia in humans
. Cardiac thrombi are present in ail adult cu-spectrin-deficient (sph/sph)
mice with severe hereditary spherocytosis, providing a model for events pre
ceding thrombosis. The current study evaluated (1) the timing of thrombosis
initiation and (2) the effect of postnatal transplantation of normal cells
on life span and thrombotic incidence in adult mice. Thrombi are detected
histologically following necropsy in untreated sph/sph mice of various ages
and are not observed until 6 weeks of age. Thrombotic incidence increases
from 50% at 6 to 7 weeks of age to 100% at 9 weeks of age. As a potential t
herapy, nonablated sph/sph neonates were transfused with either genetically
marked normal peripheral blood (PB), bone marrow (BM), or both and assesse
d for donor cells and thrombosis. A single transfusion of PB, with or witho
ut BM, significantly increases the percentage of sph/sph mice that survive
to weaning (4 weeks of age). Replacement in all sph/sph recipients is limit
ed to red blood cells (RBCs), RBCs derived from donor PB are lost within 5
weeks. PB plus BM prolongs high-level donor PB cell production better than
BM alone, Thrombotic incidence is significantly reduced in all sph/sph mice
treated with PB, BM, or both, Hence, the presence of normal blood cells in
the peripheral circulation of neonatal and adult sph/sph mice rescues the
former and abrogates the development of thrombosis in the latter.